Survey: Americans Have High Concerns About Cancer, Low Awareness of Risk Factors
October 26th 2017Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.
Read More
Will 2-Sided Risk Be a Reality in OCM?
October 24th 2017With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.
Read More
Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia
October 20th 2017CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.
Read More
Study: Ultrasound Offers Early Clues Into Development of Inflammatory Arthritis
October 17th 2017A new study suggests that ultrasound technology could allow for the earlier detection of inflammation, and therefore earlier treatment of inflammatory diseases, in patients with early joint pain.
Read More
CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference
July 21st 2017CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2—positive early breast cancer, according to research presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Read More
Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3
July 21st 2017Research presented at the 2017 American Society of Clinical Oncology Annual Meeting showed that SB3, a proposed biosimilar to trastuzumab, has comparable efficacy, safety, immunogenicity, and pharmacokinetics to the reference product based on the breast pathological complete response.
Read More